Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Greystoke

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 27, 2022
Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint InhibitorsA Greystoke
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 21, 2018
Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing BoardA Greystoke, P Mulvenna
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2012
Learning from toxicity patterns in phase I trials during the era of mechanism targeted agentsA Greystoke, M Ranson
Gastroenterology Research and Practice|September 20, 2012
How many diseases are colorectal cancer?A Greystoke, S A Mullamitha
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 1, 2019
Hypofractionated Concurrent Chemoradiation in Stage III Non-small Cell Lung Cancer: Does Planning Target Volume Size Correlate With Prognosis?M S Iqbal, A Greystoke, J Byrne
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 29, 2020
The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE PlatformC Faivre-Finn, S Brown, A Ryan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 7, 2019
Mode of Histological Diagnosis in Patients With Non-small Cell Lung Cancer Treated With Chemoradiotherapy: Its Prognostic Implication, Especially in Light of the European Durvalumab Licence?M S Iqbal, E Smith, M Cunnell, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 5, 2022
TARGET National: A UK-wide Liquid-based Molecular Profiling Programme: On Behalf of the TARGET National ConsortiumA Ortega-Franco, E Darlington, A Greystoke, et al.
British Journal of Pharmacology|September 19, 2007
Biomarker method validation in anticancer drug developmentJ Cummings, T H Ward, A Greystoke, et al.
British Journal of Cancer|September 5, 2013
The interaction between prognostic and pharmacodynamic biomarkersL Bouranis, M Sperrin, A Greystoke, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 27, 2022
Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint InhibitorsA Greystoke
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 21, 2018
Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing BoardA Greystoke, P Mulvenna
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2012
Learning from toxicity patterns in phase I trials during the era of mechanism targeted agentsA Greystoke, M Ranson
Gastroenterology Research and Practice|September 20, 2012
How many diseases are colorectal cancer?A Greystoke, S A Mullamitha
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 1, 2019
Hypofractionated Concurrent Chemoradiation in Stage III Non-small Cell Lung Cancer: Does Planning Target Volume Size Correlate With Prognosis?M S Iqbal, A Greystoke, J Byrne
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 29, 2020
The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE PlatformC Faivre-Finn, S Brown, A Ryan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 7, 2019
Mode of Histological Diagnosis in Patients With Non-small Cell Lung Cancer Treated With Chemoradiotherapy: Its Prognostic Implication, Especially in Light of the European Durvalumab Licence?M S Iqbal, E Smith, M Cunnell, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 5, 2022
TARGET National: A UK-wide Liquid-based Molecular Profiling Programme: On Behalf of the TARGET National ConsortiumA Ortega-Franco, E Darlington, A Greystoke, et al.
British Journal of Pharmacology|September 19, 2007
Biomarker method validation in anticancer drug developmentJ Cummings, T H Ward, A Greystoke, et al.
British Journal of Cancer|September 5, 2013
The interaction between prognostic and pharmacodynamic biomarkersL Bouranis, M Sperrin, A Greystoke, et al.
Pageof 4